Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study

RHHBY delivered Phase II data for enicepatide, a once-weekly dual GLP-1/GIP receptor agonist, showing HbA1c reductions of 2.65% and body weight loss of 15.5% at the 24 mg dose in type 2 diabetes patients. The drug demonstrated dose-dependent responses with minimal discontinuations due to tolerability issues.

The Swiss pharma is advancing two Phase III weight-management studies and plans to launch Phase III glycemic-control and cardiovascular trials in the first half of 2027. The timeline puts RHHBY roughly two years behind LLY and NVO, which already dominate the obesity therapeutics market with approved GLP-1 products.

Enicepatide's 15.5% weight loss figure positions it competitively against existing therapies, though real-world head-to-head data remains absent. The 2.65% HbA1c reduction addresses both metabolic control and weight management, key differentiators in a crowded field.